Par, Barr agree on sales pact to sell vomiting treatment
-
- December
- 26
Par Pharmaceutical Cos. Inc., which has manufacturing and research operations in Chestnut Ridge, said today that federal regulators have approved its application to for a generic version of ondansetron in 4- and 8-milligram tablets.
The drug prevents nausea and vomiting in some certain patients undergoing chemotherapy or radiotherapy or who have just had operations.
The drug is a generic version of GlaxoSmithKline’s Zofran ODT, Par said. U.S. annual sales of that drug are about $300 million, Par said.
The drug will be marketed by Pliva Inc., the U.S. subsidiary of Pliva d.d., a subsidiary of Barr Pharmaceuticals Inc. Barr, which has research operations in Pomona, will market and distribute the drug in the United States.
Par will make the product and the companies will share the profits.
This entry was posted
on Tuesday, December 26th, 2006 at 4:51 pm by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
